

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
28 November 2024 (28.11.2024)



(10) International Publication Number
WO 2024/241295 A1

(51) International Patent Classification:
C07K 16/24 (2006.01) A61P 17/06 (2006.01)
A61K 39/00 (2006.01)

TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(21) International Application Number:
PCT/IB2024/055099

(22) International Filing Date:
24 May 2024 (24.05.2024)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
202321036274 25 May 2023 (25.05.2023) IN

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

- with international search report (Art. 21(3))
- with sequence listing part of description (Rule 5.2(a))

(71) Applicant: SUN PHARMACEUTICAL INDUSTRIES
LIMITED [IN/IN]; Sun House, Plot No. 201 B/1, Western
Express Highway, Goregaon (E), Mumbai 400063 (IN).

(72) Inventors: YAO, Siu-Long; 78 Dillon Way, Washington
Crossing, Pennsylvania 18977 (US). KOTHEKAR, Mud-
gal; Home L and T, Emerald Isle, Tower 2, Flat 1302,
Sakivihar Road, Powai, Mumbai 400072 (IN). MEHTA,
Shantanu; 1301 Anmol Pride, Govindji Shroff Marg,
Mumbai 400104 (IN). NISHANDAR, Tushar; 3C-311,
Vrindavan CHSL (East), Raheja Township, Malad, Mum-
bai 400097 (IN).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,

(54) Title: METHODS AND COMPOSITIONS FOR TREATING PLAQUE PSORIASIS

(57) Abstract: This disclosure relates to methods of treating plaque psoriasis comprising administering an anti-IL-23p19 antibody hum13B8-b to a patient in need thereof. This disclosure also relates to pharmaceutical compositions of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the treatment plaque psoriasis in a patient. This disclosure further relates to the use of an anti-IL-23p19 antibody hum13B8-b or antigen binding fragment thereof for the manufacture of a medicament for treating plaque psoriasis in a patient. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient maintaining a Physician's Global Assessment (PGA) score of "clear" or "almost clear" with at least a 2- point reduction from Baseline, or results in the patient maintaining at least a 50% reduction in the Psoriasis Area and Severity Index (PASI 50), or results in the patient maintaining at least a 75% reduction in the Psoriasis Area and Severity Index (PASI 75), or results in the patient maintaining at least a 90% reduction in the Psoriasis Area and Severity Index (PASI 90), or results in the patient maintaining a 100% reduction in the Psoriasis Area and Severity Index (PASI 100) for at least up to about 60 weeks to at least up to about 432 weeks. In some embodiments, the disclosure relates to methods, pharmaceutical compositions, and medicaments for treating plaque psoriasis wherein treatment results in the patient experiencing no increase in adverse events (AEs), drug-related AEs, severe adverse events (SAEs), Tier 1 AEs, or Tier 2 AEs for at least up to about 60 weeks to at least up to about 432 weeks.

WO 2024/241295 A1